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AleukemicB-lymphoblastic leukemia is a clonal hematopoietic disorder of precursors B-lymphoblasts beingmost frequently
encountered in children. Expression of CD19, a pan B-cellmarker is noted in themajority of the caseswith lack of
CD19 expression being extremely rarely reported in the medical literature. We report the very rare case of a B-
lymphoblastic leukemiawith a triple negative immunophenotype: CD19 negative, CD45 negative and CD10 neg-
ative with vacuolated lymphoblasts and an aleukemic presentation in a 20-year-old man.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A clonal hematopoietic stem cell disorder acute lymphoblastic leu-
kemia affects overall 1.7 per 100,000 people annually and the percent
of survival reaches 67.5% at 5 years. The largemajority of acute lympho-
blastic leukemias (ALLs) cases develop in children less than 5 years of
age with a peak incidence of 4 to 5 cases per 100,000 people. [1,2] ALL
represents about 15% of all malignancies in 1–15 year olds, 5% in
15–19 year olds, and b10% of malignancy in N20 year olds [3]. The
large majority of these ALLs are of B-cell lineage and their correct diag-
nosis via immunophenotyping is essential for their treatment. Most of
the B-lymphoblastic leukemia cases are CD19 and CD45 positive, co-
express cytoplasmic CD79a, terminal deoxynucleotidyl transferase
(TdT) and HLA-DR and are CD10 positive. To our knowledge, there has
been only oneother case of CD45 negative CD19 negative B lymphoblas-
tic leukemia reported in the medical literature [4]; however, it lacks the
morphological features of the current case.2. Case report
A20-year-old, Caucasianmanwith a 20-lb unintentionalweight loss
over the course of 2 months and recent heavy night sweats, presentedst regarding the publication of
. This is an open access article underwith intermittent spasm–back pain with radiation to his chest and on-
going cough. The patient denied fever, fatigue, shortness of breath, or
dyspnea.
Complete blood cell counts on admission were remarkable for mild
leukopenia (white blood cells 2.5 × 109/L), mild anemia (hemoglobin
12.7 g/dL), and mild thrombocytopenia (platelets 144 × 109/L). Rare
blasts were identiﬁed on scanning of the peripheral blood smear, and
theywere ofmedium to large size and containedmany intracytoplasmic
ﬁne vacuoles. An anterior mediastinal mass and a small right pleural ef-
fusion were noted on a chest x-ray and a computed tomography (CT)
scan examination of the chest, abdomen and pelvis was remarkable
for an 11.4 × 9.1 cm anterior mediastinal mass with mass effect
(Fig. 1) on the superior vena cava and left mainstem bronchus. There
was also subcarrinal, left hilar, right axillary, celiac, peripancreatic,
periaortic and periureteral lymphadenopathy and ill-deﬁned small
rounded cortical lesions were noted in both kidneys. The patient
underwent bilateral iliac crest bone marrow biopsies and aspirate ex-
amination with immunophenotypic analysis by both ﬂow cytometry
and immunohistochemistry, with associated molecular and cytogenet-
ic/FISH analysis. Based on the ﬁndings a diagnosis of B lymphoblastic
leukemia, with an unusual immunophenotype (CD10 negative, CD19
negative, CD45 negative) was rendered. The patient started induction
chemotherapy on the DFCI 05-001 protocol. Multiple complications de-
veloped during his induction and oral chemotherapy treatment includ-
ing Staphylococcus bacteremia, recurrent pancreatitis, and recurrent
pneumonia and bronchiectasis. His oral chemotherapy maintenance
course was also extended by nine months due to a period of non-
compliance during his initial treatment. Two and a half years after thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. CT image of the anterior mediastinal mass.
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on maintenance chemotherapy. His most recent CBC indices are within
reference ranges.
3. Materials and methods
Immunohistochemistry, ﬂow cytometry immunophenotypic analy-
sis, karyotype analysis, in situ hybridization studies (FISH), and PCR
studies were performed as for the clinical workup of this case. Immuno-
histochemical stains were performed on bone marrow biopsy cores
using: CD3 (monoclonal PS1, Novocastra), PAX-5 (BV6, Diagnostic
Biosystems), CD79a (monoclonal JCB117, Cell Marque), TdT (monoclo-
nal SEN28, Vector), CD34 (monoclonal QBEnd/10, BioGenex), CD43
(monoclonal DF-Ti and MT1, DAKO and BioGenex coctail),
myeloperoxidase (polyclonal, DAKO), CD68 (monoclonal KPI, Cell
Marque), lysozyme (polyclonal, DAKO), and CD117 (Diagnostic
Biosystems) using an automated immunostainer (DakoCytomation,
Inc, Carpinteria, California). The 5-color ﬂow cytometry studies were
performed on bone marrow aspirate samples anticoagulated with
EDTA, using Beckman Coulter IOTest monoclonal antibodies (Hialeah,
Florida) analyzed on a Beckman Coulter FC500 ﬂow cytometer using
CXP software. The blast populations were Boolean gated based on spe-
ciﬁc antigen expression patterns, with a marker being considered posi-
tive when expressed in more than 20% of the blast forms above the
isotypic control. The karyotype analysis, FISH and molecular studies
were performed based on the classic recognized protocols.
4. Results
Patient's bone marrow examination was remarkable for a markedly
hypercellular marrow (approx. 90%–100% on right side, and approx.
90%–95% on the left side) and a 500-cell count bone marrow aspirate
differential had 80.7% blasts, heterogenous in size with round to ovoid
to slightly irregular nuclei with open chromatin, one to multiple nucle-
oli, moderate amounts of dense basophilic cytoplasm, andmost unique-
ly, ﬁne intracytoplasmic vacuoles (Fig. 2). The blasts were positive for
Oil Red O (Fig. 3A), and negative formyeloperoxidase by cytochemistry,
and immunohistochemistry (Fig. 3B). By ﬂow cytometry
immunophenotypic analysis of a bone marrow aspirate sample identi-
ﬁed 70% blasts, CD45 negative (Fig. 4) and CD19 (Fig. 5A), and positivefor CD34 (Fig. 5A), TdT, HLA-DR, surface CD22 (Fig. 5B), CD24, CD9,
CD38, CD58, and CD138. They are also negative for CD20, cytoplasmic
CD22, cytoplasmic mu, surface immunoglobulin light chains, surface
immunoglobulin M, CD10, CD13, CD33, sCD3, and cCD3, CD5, CD4,
CD8, CD2, CD7, CD1a and cytoplasmicmyeloperoxidase. By immunohis-
tochemistry the blast population was positive for PAX-5 (Fig. 6 A), TdT
(Fig. 6B), and CD34 and had variable CD43 positivity (Fig. 7A) and
scattered blasts were CD79a positive (b5%) (Fig. 7B).
Molecular studies performed on a fresh bone marrow aspirate sam-
ple were positive for immunoglobulin heavy-chain gene rearrange-
ments and negative for T-cell receptor beta and gamma gene
rearrangements, and the analyzed karyotype was remarkable for 49
XY, der(7)inv(7)(p15q11.2), add(7)(p15)(q32),+20[cp2]/
91,idemx2,−Y,−Y,add(1),(q42),add(2)(q33), −15[6]/46,XY[12]
(Fig. 8).
Fluorescence in situ hybridization studies (FISH) were also per-
formed and were negative for BCR-ABL1 dual fusion probe, being posi-
tive for gains of ABL1 (four signals) and BCR (four signals) in 59% off
the interphase cells examined. FISH studies were negative for MLL
gene rearrangements, but positive for gain of MLL (11q23), with four
MLL signals per cell noted in 60% of the interphase cells examined,
and negative for ETV6-RUNX1 fusion, but positive for gains of ETV6
and RUNX1— 4 signals per cell noted in 61% of the interphase cells an-
alyzed. FISH studies were also negative for deletion 9p21, but positive
for gain of chromosome 9 and were also positive for gains of chromo-
somes 4, 10 and 17.
5. Discussion
Immunophenotypic variations of leukemic B lymphoblasts have
been extensively reported in the medical literature and in a subset of
cases they have prognostic implications and may indicate association
with speciﬁc chromosomal abnormalities: expression ofmyeloid associ-
ated antigens and expression of interleukin receptor CD25 predict for
the presence of BCR/ABL fusion transcripts [5], and cases with t(4;11)
are likely to be CD19 negative, CD10 negative, CD24 negative [6] etc.
In their study, Ratei et al. [7] investigated 638 patients with acute
lymphoblastic leukemia and only a small subset (68 cases, 12.9%) lacked
CD45 expression. When cell cycle analysis was performed in cases of
ALLwith CD45 negative and CD45 positive subsets of blasts, the authors
noticed that the CD45 negative subpopulation had a higher percentage
of cells in S-phase and concluded that the lack of CD45 expression con-
tributes to the identiﬁcation of a distinct functional and immunological
subgroup of B-cell precursor ALL, but did not signiﬁcantly impact the
clinical behavior or the outcome of treated childhood ALL [6]. Lack of
CD45 expression was associated in the case series of Behm et al. [8]
with signiﬁcantly lower leukocyte counts and serum lactic dehydroge-
nase levels and was more likely to have leukemic cell hyperdiploidy
greater than 50 when compared with cases positive for the antigen.
Only in a very small number of acute B-lymphoblastic leukemia
cases, leukemic blasts are lacking expression of CD19 and in a couple
of cases [9,10] acute B-lymphoblastic leukemia was associated with
hypercalcemia.
Cases with dim CD45 expression and CD19 negative B-
lymphoblastic leukemia have been also reported [7], but the lack of
both CD45 and CD19 expression was only once noted in the English lit-
erature [4]. The case presented byMoon et al. [4] was of a 6-year old girl
who had variably sized blasts, with high nuclear to cytoplasmic ratio
and distinct nucleoli, negative for CD45, CD19, CD10, CD20, CD3, CD5,
CD7, CD56/16, CD13, and CD33 and positive for CD22, TdT, and CD34.
By immunohistochemistry they were positive for CD79a, CD10, TdT
and CD99. A normal karyotype was reported but ampliﬁcation of the
MLL gene was suggested by ﬂuorescent in situ hybridization.
Our case had a highly atypical immunophenotype being positive for
blast markers (CD34 and TdT), with immunophenotypic expression
reminiscent of both plasma cells (CD45 negative, CD38 and CD138
Fig. 2. Blast with intracytoplasmic vacuoles; peripheral blood smear,Wright–Giemsa stain, immersion oil, 1000×. (A) Numerous vacuolated blasts; bonemarrow aspirate smear,Wright–
Giemsa stain, immersion oil, 1000× (B).
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CD79a positivity) and was associated with the presence of immuno-
globulin heavy chain gene rearrangements. The blasts lacked CD10
and CD19 expression and had a complex karyotype. Their morphology
was different from the one reported in the prior CD19 and CD45 nega-
tive B-lymphoblastic leukemia [4] being more in keeping with the L3
morphology (Burkitt leukemia/lymphoma-like cells).
Furthermore, while the aleukemic presentation and the lack of CD19
expression are similar to the B lymphoblastic leukemia case presented
by Hussein et al. [9], our patient lacked hypercalcemia and lytic bone le-
sions, and the immunophenotype of his blasts was remarkable for the
absence of both CD45 and CD10 expression.
Of note, the karyotype analysis revealed two related clonal subpop-
ulations one near hyperdiploid and the second hyperdiploid (tetra-
ploid), both associated with trisomy 20 and a complex rearrangement
of chromosome 7, resulting in loss of 7p. The second clone, had also
loss of chromosomes Y and 15, and there was an additional chromo-
some material of unknown origin attached of chromosomes 1 and 2
(picture not shown).Fig. 3. Blasts positive with Oil Red O; bone marrow aspirate, immersion oil, 10The patient's complex karyotype with two clonal populations with
almost hyperdiploid and hyperdiploid/tetraploid chromosome comple-
ment may suggest a better clinical course; however, the gains of chro-
mosomes 4, 10 and 17, indicators of a good outcome, are present here
as tetrasomies not triple trisomies [10,11].
Abnormalities involving chromosome 7 (including der(7) and
inv(7)(p15q11.2)) and monosomy of chromosome 15, have been re-
ported in cases of hypodiploid B lymphoblastic leukemia [12], while
add 2(q33) has been reported in association with B lymphoblastic leu-
kemia as a single cytogenetic abnormality or associatedwith other chro-
mosomal abnormalities in cases with hypodiploid and diploid number
of chromosomes [13–15].
Of interest in our case remains the reported loss of 7p in one of these
clonal populations that may suggest loss of IKFZ1. Alterations of IKFZ1
were previously identiﬁed in 13% to 28.6% of the patients with Ph–
acute B-lymphoblastic leukemias [16,17]; however, their association
with an adverse treatment outcome as reported by some authors [17]
is not seen by all [18].00×. (A) Anti-myeloperoxidase antibody; bone marrow biopsy, 500× (B).
Fig. 4. Flow cytometry immunophenotypic analysis of the bone marrow aspirate. The
blasts are CD45 negative.
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blasts, in the differential diagnosis, a possible acute undifferentiated leu-
kemia may be suggested. However, due to the combined expression of
surface CD22, a regulator of B-cell receptor signaling [19], CD138, a hep-
arin sulfate-rich membrane glycoprotein expressed in pre-B-cells and
IgG producing plasma cells [20], CD43, a marker noted in early imma-
ture hematogones [21] and also in up to 75% of the precursor B lympho-
blastic leukemia/lymphomas [21,22] and PAX-5 positivity, a
transcription marker expressed throughout the B-cell maturation [23]
with the associated immunoglobulin heavy chain gene rearrangement
[24], early differentiation toward the B-cell lineage and, thus, a diagno-
sis of B-lymphoblastic leukemia were favored.
To date, two and a half years after his diagnosis of B-lymphoblastic
leukemia our patient remained in hematological remission.
The rare aleukemic presentation of a triple CD45, CD19 and CD10
negative B-lymphoblastic leukemia with vacuolated blast population
was presented. While the unusual immunophenotype may represent a
diagnostic challenge, especially when immunophenotypic analysis is
limited to ﬂow cytometry, knowledge of the underlying cytogenetic ab-
normalities may bring information regarding the leukemogenesis and
the clinical course of this unusual leukemia subtype.References
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